Immune-related adverse events not associated with survival in advanced or metastatic gastroesophageal cancers
{{output}}
Immune checkpoint inhibitors (ICIs) have shown promise in the treatment of gastric and oesophageal cancers (GEC). Despite their promising efficacy, ICIs have been associated with unique side effects known as immune-related adverse events (IRAEs). Several studi... ...
